Kimia Biosciences Ltd.
BSE: 530313
₹31.80
₹-0.87
(-2.66%)
As on 17-Jun-2026IST
Market cap
₹150 Cr
Revenue (TTM)
₹115 Cr
P/E Ratio
20.2
P/B Ratio
8.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹7 Cr
-
ROE
186.7 %
-
ROCE
42.2 %
-
Industry P/E
34.2
-
EV/EBITDA
11.6
-
Debt to Equity
1.3
-
Book Value
₹3.7
-
EPS
₹1.6
-
Face value
1
-
Shares outstanding
47,312,741
10 Years Aggregate
CFO
₹26.88 Cr
EBITDA
₹31.82 Cr
Net Profit
₹-1.73 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kimia Biosciences
| -6.3 | -10.8 | 11.3 | -34.8 | -2.4 | -8.7 | -- |
|
BSE Healthcare
| 8.3 | -0.3 | 11.2 | 6.5 | 23.4 | 13.3 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Kimia Biosciences
| -24.3 | 24.4 | -14.4 | -30.2 | 20.3 | 131.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kimia Biosciences
|
31.8 | 150.5 | 114.9 | 7.4 | 9.0 | 50.7 | 20.2 | 8.5 |
| 3,079.4 | 38,525.2 | 5,452.9 | 1,056.0 | 22.4 | 23.9 | 36.5 | 8.5 | |
| 8,512.5 | 21,301.5 | 2,275.6 | 187.5 | 10.3 | 22.9 | 113.6 | 24.4 | |
| 2,334.9 | 17,735.4 | 2,187.2 | 649.7 | 31.5 | 19 | 27.7 | 4.9 | |
| 1,792.4 | 10,962.0 | 1,403.2 | 185.1 | -- | 27.4 | 59.2 | 14.7 | |
| 1,411.1 | 19,540.8 | 3,129.4 | 647.4 | 26.9 | 18.1 | 31.5 | 5.0 | |
| 2,195.6 | 35,257.9 | 4,147.8 | 709.5 | 22.3 | 19.1 | 49.7 | 8.5 | |
| 4,493.5 | 20,590.8 | 2,519.7 | 722.4 | 33.6 | 18.8 | 28.5 | 4.9 | |
| 6,249.5 | 10,359.8 | 1,408.0 | 326.9 | 30.8 | 57.1 | 31.7 | 19.8 | |
| 572.4 | 11,203.9 | 1,538.1 | 226.2 | 20.4 | 9 | 46 | 4.3 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Kimia Biosciences
Laurel Organics Ltd manufactures and sells pharmaceutical-bulk drugs in India. The company offers Benfotiamine, Cilnidipine, Gliclazide, Levosulpride, Rosuvastatin Calcium, Tranexamic Acid, Benidipine, Teneligliptin Hydrate Hydrobromide, Acotiamide,... Citicoline Sodium, Luliconazole, Deflazacort, Voglibose, Oxaceprol, Ursodeoxycholic Acid, Bacitracin Zinc, Isotretinoin, and Tretinoin, as well as vitamin B1, calcium channel blocker, central stimulant/nootropic agent, and choleretic agent. It also provides products for various therapeutic categories, which comprise antidiabetic, antipsychotic, antihyperlipidemic, hemostatic, antihypertensive, antidiabetic, antiemetic, anti-fungal, anti-inflammatory, and anti-acne. The company was incorporated in 1993 and is based in New Delhi, India. Laurel Organics Ltd is a subsidiary of Kimia Biosciences Ltd. Read more
-
Incorporated
1993
-
Chairman
Sameer Goel
-
Managing Director
Sameer Goel
-
Headquarters
Bhondsi, Haryana
-
Website
Looking for more details about Kimia Biosciences Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsOutcome Of The Board Meeting Held On 29 May 2026
29-May-2026Clarification sought from Kimia Biosciences Ltd
13-Apr-2026No News & Announcements are available.
FAQs for Kimia Biosciences
What is the current share price of Kimia Biosciences Ltd Today?
The share price of Kimia Biosciences Ltd is ₹31.80 (BSE) as of 17-Jun-2026 IST. Kimia Biosciences Ltd has given a return of -2.39% in the last 3 years.
What is the current PB & PE ratio of Kimia Biosciences Ltd?
The P/E ratio of Kimia Biosciences Ltd is 20.24 times as on 17-Jun-2026, a 41 discount to its peers’ median range of 34.20 times.
The P/B ratio of Kimia Biosciences Ltd is 8.49 times as on 17-Jun-2026, a 75 premium to its peers’ median range of 4.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
20.92
|
20.18
|
|
2024
|
0.00
|
796.60
|
|
2023
|
0.00
|
28.15
|
|
2022
|
0.00
|
11.95
|
|
2021
|
35.17
|
9.74
|
What is the 52 Week High and Low of Kimia Biosciences Ltd?
The 52-week high and low of Kimia Biosciences Ltd are Rs 86.85 and Rs 23.20 as of 18-Jun-2026.
What is the market cap of Kimia Biosciences Ltd?
Kimia Biosciences Ltd has a market capitalisation of ₹ 150 Cr as on 17-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kimia Biosciences Ltd?
Before investing in Kimia Biosciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.